Cargando…

Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis

Normal hematopoietic function is maintained by a well-controlled balance of myelomonocytic, megaerythroid and lymphoid progenitor cell populations which may be skewed during pathologic conditions. Using semisolid in vitro cultures supporting the growth of myelomonocytic (CFU-GM) and erythroid (BFU-E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geissler, Klaus, Gisslinger, Bettina, Jäger, Eva, Jäger, Roland, Schiefer, Ana-Iris, Bogner, Edith, Fuchs, Elisabeth, Schischlik, Fiorella, Alpar, Donat, Simonitsch-Klupp, Ingrid, Kralovics, Robert, Gisslinger, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464756/ https://www.ncbi.nlm.nih.gov/pubmed/32824053 http://dx.doi.org/10.3390/cancers12082291

Ejemplares similares

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype
por: Heibl, Sonja, et al.
Publicado: (2020)

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
por: Milosevic Feenstra, Jelena D., et al.
Publicado: (2022)

Allelic imbalance in CALR somatic mutagenesis
por: Harutyunyan, A S, et al.
Publicado: (2015)

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia
por: Geissler, Klaus, et al.
Publicado: (2019)

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans
por: Kornienko, Aleksandra E., et al.
Publicado: (2016)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'
por: Gisslinger, H, et al.
Publicado: (2017)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

Multistep pathogenesis of chronic myelomonocytic leukemia in patients
por: Geissler, Klaus, et al.
Publicado: (2022)

Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors
por: Geissler, K, et al.
Publicado: (2016)

Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Applicant perceptions of selection methods for health professions education: Rationales and subgroup differences
por: Fikrat‐Wevers, Suzanne, et al.
Publicado: (2022)

Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia
por: Lackner, David, et al.
Publicado: (2022)

Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia
por: Machherndl‐Spandl, Sigrid, et al.
Publicado: (2021)

Significance of reduced renal function in patients with chronic myelomonocytic leukemia
por: Heschl, Julia, et al.
Publicado: (2022)

Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia
por: Weinfurtner, Christoph, et al.
Publicado: (2022)

Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
por: Buxhofer‐Ausch, Veronika, et al.
Publicado: (2020)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
por: Them, Nicole CC, et al.
Publicado: (2015)

Significance of C-reactive protein in patients with chronic myelomonocytic leukemia
por: Liang-Fonseca, Jian, et al.
Publicado: (2022)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
por: Hose, Dorothea, et al.
Publicado: (2020)

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
por: Kubesova, B, et al.
Publicado: (2018)

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
por: Vannucchi, Alessandro M., et al.
Publicado: (2019)

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches
por: Geissler, Klaus
Publicado: (2021)

Current and future treatment options for polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2015)

The effect of different skew quadrupole correction schemes on the dynamic aperture of LHC
por: Ziemann, Volker
Publicado: (1994)

Influence of different skew angles of the submerged vane on pressure flushing performance
por: Beiramipour, Sepideh, et al.
Publicado: (2023)

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2016)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2017)

Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
por: Geissler, Klaus, et al.
Publicado: (2020)

Fictitious Inhibitory Differences: How Skewness and Slowing Distort the Estimation of Stopping Latencies
por: Verbruggen, Frederick, et al.
Publicado: (2013)

Individual differences in skewed financial risk-taking across the adult life span
por: Seaman, Kendra L., et al.
Publicado: (2017)

The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies
por: Gaiger, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g6v76c1rrlmihb5ajl4j94k0r6